| human | Q5 |
| P227 | GND ID | 1022936808 |
| P12541 | Ludzie Nauki ID (new) | BNTCLYWcfQs |
| P496 | ORCID iD | 0000-0001-9181-5026 |
| P7293 | PLWABN ID | 9810650295705606 |
| P3124 | Polish scientist ID (deprecated) | 107202 |
| P3829 | Publons author ID | 2510751 |
| P1053 | ResearcherID | I-2844-2014 |
| P214 | VIAF ID | 162363407 |
| P10832 | WorldCat Entities ID | E39PBJfrHcBHYFb78XR4t4TvHC |
| P512 | academic degree | habilitation | Q308678 |
| doctorate | Q849697 | ||
| scientific professorship degree | Q55695329 | ||
| P27 | country of citizenship | Poland | Q36 |
| P184 | doctoral advisor | Jan Lubiński | Q11718282 |
| P185 | doctoral student | Marek Jasiówka | Q60636828 |
| P69 | educated at | Pomeranian Medical University | Q694887 |
| P108 | employer | Pomeranian Medical University | Q694887 |
| P734 | family name | Byrski | Q65515001 |
| Byrski | Q65515001 | ||
| Byrski | Q65515001 | ||
| P101 | field of work | oncology | Q162555 |
| P735 | given name | Tomasz | Q17644435 |
| Tomasz | Q17644435 | ||
| Antoni | Q17480899 | ||
| Antoni | Q17480899 | ||
| P1412 | languages spoken, written or signed | Polish | Q809 |
| P1559 | name in native language | Tomasz Byrski | |
| P106 | occupation | physician | Q39631 |
| researcher | Q1650915 | ||
| oncologist | Q16062369 | ||
| P21 | sex or gender | male | Q6581097 |
| Q36108172 | A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet |
| Q57666866 | A Range of Cancers Is Associated with the rs6983267 Marker on Chromosome 8 |
| Q43566825 | A common nonsense mutation of the BLM gene and prostate cancer risk and survival |
| Q35447197 | A common variant of CDKN2A (p16) predisposes to breast cancer |
| Q80081672 | A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland |
| Q61945696 | A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer |
| Q34548008 | A high proportion of founder BRCA1 mutations in Polish breast cancer families |
| Q36927109 | A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q80243539 | A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population |
| Q79652344 | A survey of preventive measures among BRCA1 mutation carriers from Poland |
| Q71579903 | Abnormalities of chromosome 5q correlate with morphologic features of better prognosis in clear cell renal carcinomas |
| Q87587823 | Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study |
| Q36594121 | An inherited NBN mutation is associated with poor prognosis prostate cancer |
| Q37056869 | Are two-centimeter breast cancers large or small? |
| Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
| Q113241843 | Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q40521165 | Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland |
| Q53567982 | BARD1 and breast cancer in Poland. |
| Q54409850 | BRCA1 mutations and colorectal cancer in Poland. |
| Q43632939 | BRCA1 mutations and prostate cancer in Poland |
| Q46054315 | BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms |
| Q44949616 | BRCA1-positive breast cancers in young women from Poland. |
| Q81892020 | Breast cancer predisposing alleles in Poland |
| Q73400704 | Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland |
| Q57666904 | Breast cancer susceptibility genes |
| Q34306552 | CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland |
| Q43806333 | CDKN2A common variant and multi-organ cancer risk--a population-based study |
| Q45261315 | CDKN2A common variants and their association with melanoma risk: a population-based study. |
| Q54574835 | CDKN2A-positive breast cancers in young women from Poland. |
| Q112162492 | CHAPTER 22. Selenium and Cancer |
| Q34551970 | CHEK2 is a multiorgan cancer susceptibility gene |
| Q53362846 | CHEK2 mutations and HNPCC-related colorectal cancer. |
| Q46250042 | CHEK2 mutations as markers for high risk of breast cancer |
| Q80128998 | CHEK2-positive breast cancers in young Polish women |
| Q57666910 | CYP1B1 and predisposition to breast cancer in Poland |
| Q37222641 | Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband |
| Q73333633 | Characteristics of selected features of hereditary ovarian cancer in carriers of constitutional BRCA1 gene mutation |
| Q77447971 | Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation |
| Q37249356 | Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation |
| Q59288510 | Cisplatin in breast cancer treatment in BRCA1 carriers |
| Q53088764 | Clinical characteristics of breast cancer in patients with an NBS1 mutation. |
| Q73039579 | Clinical characteristics of hereditary ovarian cancer (HOC) in Poland |
| Q79843110 | Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2 |
| Q37363736 | Clinical genetic services for familial breast cancer in Poland |
| Q41748948 | Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis |
| Q41869270 | Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients |
| Q47110534 | Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34949394 | Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q34585088 | Common variants of DNA repair genes and malignant melanoma |
| Q43825646 | Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers |
| Q45906878 | Copper as diagnostic marker of cancers. |
| Q89080190 | Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility |
| Q41839357 | Coverage of the genetic background of breast cancer in the polish population |
| Q48353045 | Detection of germline mutations in the BRCA1 gene by RNA-based sequencing |
| Q79811213 | Direct-to-patient BRCA1 testing: the Twoj Styl experience |
| Q40821559 | Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? |
| Q80514712 | Early radiation exposures and BRCA1-associated breast cancer in young women from Poland |
| Q53316752 | Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. |
| Q79986282 | Epistatic relationship between the cancer susceptibility genes CHEK2 and p27 |
| Q61946721 | Erratum: Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? |
| Q46236360 | Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention |
| Q46250083 | Folic acid and cancer risk in BRCA1 carriers. |
| Q24540270 | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer |
| Q77642899 | Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families |
| Q57666860 | Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology |
| Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34572576 | Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? |
| Q43075069 | Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States |
| Q61945792 | Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study) |
| Q41010238 | Germline RECQL mutations are associated with breast cancer susceptibility |
| Q84632533 | Hereditary breast and ovarian cancer |
| Q43683502 | Hereditary ovarian cancer in Poland. |
| Q38806848 | Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial |
| Q55717426 | Impact of BRCA1 mutation on survival after early onset breast cancer. |
| Q81425159 | Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland |
| Q42550934 | Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk |
| Q46130512 | Iron as diagnostic marker of cancer. |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q81803706 | Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland |
| Q42244979 | Low-risk Genes and Multi-organ Cancer Risk in the Polish Population |
| Q45956204 | Lynch syndrome mutations shared by the Baltic States and Poland. |
| Q61946725 | MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk |
| Q46130429 | Magnesium as a diagnostic marker of cancer. |
| Q51830222 | Male to female ratio among offspring of BRCA1 mutation carriers. |
| Q34988799 | Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families |
| Q47133182 | Meeting abstracts from the Annual Conference on Hereditary Cancers 2015: Szczecin, Poland. 24-25 September, 2015. |
| Q50233852 | Meeting abstracts from the Annual Conference on Hereditary Cancers 2016: Szczecin, Poland. 14-15 September 2016. |
| Q79298327 | Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks |
| Q61946734 | Molecular Analyses in Diagnosis of High Genetic Predispositions to Malignancies |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q54314566 | Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. |
| Q55403547 | Mutations spectrum in hereditary disorders predisposing to occurrence of intestine polyposis in Poland. |
| Q61946727 | NOD2 variants and the risk of malignant melanoma |
| Q46250020 | Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment |
| Q112576545 | Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience |
| Q59255480 | Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients |
| Q61946712 | New EPCAM founder deletion in Polish population |
| Q43073995 | Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland |
| Q35559901 | Novel germline mutations in the adenomatous polyposis coli gene in Polish families with familial adenomatous polyposis |
| Q33327308 | Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q54308947 | Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. |
| Q43222794 | Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy |
| Q38240441 | Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients |
| Q36132338 | Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers |
| Q46130542 | Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. |
| Q81601356 | Pathology of breast cancer in women with constitutional CHEK2 mutations |
| Q60585018 | Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study |
| Q51672667 | Pleomorphic adenoma of salivary glands does not appear to be a BRCA-1-dependent tumour in a Polish cohort. |
| Q42244986 | Population Screening of CHEK2 Mutations in Poland |
| Q42244983 | Population screening for cancer family syndromes in the west pomeranian region of poland |
| Q49787762 | Predictors of survival for breast cancer patients with a BRCA1 mutation. |
| Q61946726 | Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer |
| Q36494555 | Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer |
| Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
| Q122937357 | Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer |
| Q45185763 | Recurrent mutations of BRCA1 and BRCA2 in Poland: an update |
| Q36538025 | Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland |
| Q34579373 | Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers |
| Q81688258 | Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients |
| Q36924418 | Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer |
| Q51421155 | Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. |
| Q59288376 | Selenium (Se) and breast cancer risk |
| Q46250119 | Selenium (Se) and the risk of breast, ovarian and prostate cancers |
| Q46738357 | Selenium and genotypes as marker of risk in BRCA1 mutation carriers |
| Q50219543 | Selenium and the risk of cancer in BRCA1 carriers. |
| Q38359733 | Selenium as a marker of cancer risk and of selection for control examinations in surveillance |
| Q46130885 | Selenium as diagnostic marker of cancers. |
| Q38067529 | Selenium as marker for cancer risk and prevention |
| Q44732177 | Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? |
| Q54375866 | Survival from breast cancer in patients with CHEK2 mutations. |
| Q43425193 | Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk |
| Q36755366 | Systemic treatment for hereditary cancers: a 2012 update |
| Q44251009 | Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer |
| Q44306036 | The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation |
| Q33722537 | The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs |
| Q45114407 | The 3020insC allele of NOD2 predisposes to early-onset breast cancer |
| Q40989977 | The Conductivity and pH Values of Dispersions of Nanospheres for Targeted Drug Delivery in the Course of Forced Equilibrium Dialysis |
| Q40776729 | The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation |
| Q44733776 | The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland |
| Q79776026 | The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers |
| Q80436355 | The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women |
| Q91565756 | The diameter of metastasis in positive sentinel lymph node biopsy affects axillary tumor load in early breast cancer |
| Q38777240 | The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients |
| Q37613551 | The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation |
| Q36898423 | The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study |
| Q40137412 | The presence of prostate cancer at biopsy is predicted by a number of genetic variants |
| Q35907001 | The risk of breast cancer in women with a BRCA1 mutation from North America and Poland |
| Q46738314 | The risk of breast cancer in women with a CHEK2 mutation |
| Q61952806 | The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men |
| Q43073174 | Transmission of mutant alleles to female offspring of BRCA1 carriers in Poland |
| Q55036759 | Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers. |
| Q33654709 | Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility |
| Q46512471 | Vitamin D receptor variants and breast cancer risk in the Polish population |
| Q84398671 | Vitamin D receptor variants and the malignant melanoma risk: a population-based study |
| Q46738293 | Why choose the treatment with cisplatin for BRCA1 breast cancers patients? |
| Q52570748 | XPD common variants and their association with melanoma and breast cancer risk. |
| Q46660029 | Zinc and breast cancer risk |
| Q45946070 | Zinc as diagnostic marker of cancers. |
| Q81029752 | [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method] |
| Q60636828 | Marek Jasiówka | doctoral advisor | P184 |
| Q11718282 | Jan Lubiński | doctoral student | P185 |
Search more.